Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab in Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
NCT05636176Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- May 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 46
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Ziltivekimab with Placebo (2 arms). Primary endpoint: Time to First Occurrence of a Composite Heart Failure Endpoint Consisting of: Cardiovascular (CV) Death, Heart Failure (HF) Hospitalisation or Urgent HF Visit at 48 months. Started May 2023; status: terminated.
02
Drugs
ziltivekimab
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05636176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636176.